https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
Five GOSH clinicians recognised with professorial appointments at UCL
Five clinician researchers from GOSH have been promoted to professor by University College London (UCL), recognising their outstanding contributions to research, innovation and child health.
From staff idea to global innovation: Taking the next step towards improving patient safety
A simple idea developed by a GOSH clinician has secured a commercial partner.
Four research projects receive funding to improve understanding and treatment of childhood cancer
Researchers at Great Ormond Street Hospital (GOSH) and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have received funding from The Little Princess Trust for four childhood cancer research projects.
New study brings hope for children with rare life-threatening kidney disease
New research funded by Great Ormond Street Hospital Charity (GOSH Charity), LifeArc and Kidney Research UK has taken an important step towards developing a new treatment for serious genetic kidney diseases affecting children.